"GLP-3" is a research label for next-generation incretin compounds designed to act on more than one receptor at once. The thinking is simple: if GLP-1 alone is good and GLP-1 plus GIP is better, what happens when you add a third receptor to the mix? This article reviews the science behind multi-receptor agonists.
From GLP-1 to Multi-Receptor Agonists
GLP-1 receptor agonists like semaglutide and liraglutide changed metabolic research over the past decade. They lower blood glucose, slow gastric emptying, and reduce appetite. But the GLP-1 receptor is just one piece of a larger system that also includes GIP and glucagon receptors.
Researchers found that activating two of these receptors together produced stronger metabolic effects than activating one. Jastreboff and colleagues (2022) reported that tirzepatide, a dual GIP/GLP-1 agonist, produced up to 22.5% body weight reduction in the SURMOUNT-1 trial. That established multi-receptor approaches as a serious direction in metabolic research.
What "GLP-3" Compounds Are Designed to Do
"GLP-3" research compounds aim to take the multi-receptor idea further. Many are designed to engage GLP-1, GIP, and glucagon receptors simultaneously. The reasoning is that glucagon, while traditionally framed as the opposite of insulin, also influences energy expenditure when activated alongside GLP-1.
Finan et al. (2015) demonstrated that a balanced triple agonist targeting GLP-1, GIP, and glucagon receptors reduced body weight and improved metabolic parameters in diet-induced obese mice — and did so more effectively than any dual combination tested in the same study.
The challenge is balance. Triple agonists need carefully tuned activity at each receptor. Too much glucagon activation could raise blood glucose; too little, and the energy-expenditure benefit is lost.
Research Endpoints and Models
Most published work on next-generation incretin compounds uses rodent models of diet-induced obesity, type 2 diabetes models, and metabolic disease models. Endpoints include body weight, food intake, glucose tolerance, insulin sensitivity, and lipid panels.
More recent studies look at energy expenditure, brown adipose tissue activity, and liver fat content — endpoints that align with the glucagon component of triple agonist signaling. Researchers comparing single-, dual-, and triple-receptor agonists in the same model can build a clearer picture of which combination produces which effect.
Open Questions
Triple agonists are newer than the well-studied GLP-1 class, and long-term data is still accumulating. Researchers continue to explore optimal receptor activity ratios, off-target effects, and how multi-receptor signaling reshapes metabolic homeostasis over time.
Receptor desensitization is another area under study. Sustained activation of any receptor can change how cells respond, and balancing three at once adds complexity.
The next-generation metabolic peptide field is moving quickly, but many of the most interesting questions — including durability, tissue specificity, and chronic outcomes — are still open. All compounds discussed here are intended for research use only and are not for human consumption.